LitAlert ~~ GeneLit.com

    • K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review.
    • Baughan S, Tainsky MA.
    • Cancers (Basel). 2021 Jan 25;13(3):E447. doi: 10.3390/cancers13030447.
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • Economic impact of multigene panel testing for hereditary breast and ovarian cancer.
    • Byfield SD, Wei H, DuCharme M, Lancaster JM.
    • J Comp Eff Res. 2021 Jan 25. doi: 10.2217/cer-2020-0192. Epub ahead of print.
    • Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
    • McAlarnen L, Stearns K, Uyar D.
    • Appl Clin Genet. 2021 Jan 14;14:1-9. doi: 10.2147/TACG.S245021.
    • New Approach for Risk Estimation Algorithms of BRCA1/2 Negativeness Detection with Modelling Supervised Machine Learning Techniques.
    • Yazici H, Odemis DA, Aksu D, Erdogan OS, Tuncer SB, Avsar M, Kilic S, Turkcan GK, Celik B, Aydin MA.
    • Dis Markers. 2020 Dec 9;2020:8594090. doi: 10.1155/2020/8594090.
    • Age of natural menopause onset in BRCA1/2 carriers - systematic review and meta-analysis.
    • Kepczynski L, Polatynska K, Nykel A, Salamunia J, Kaluzewski T, Kuzawczyk A, Gach A.
    • Prz Menopauzalny. 2020 Dec;19(4):171-173. doi: 10.5114/pm.2020.101946. Epub 2021 Jan 7.
    • Ovarian cancer risk assessment in the era of next-generation sequencing.
    • Bonadio RC, Crespo JR, Estevez-Diz MDP.
    • Ann Transl Med. 2020 Dec;8(24):1704. doi: 10.21037/atm-20-1582.